Comparative Pharmacology
Head-to-head clinical analysis: PARAFON FORTE DSC versus ZANAFLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARAFON FORTE DSC versus ZANAFLEX.
PARAFON FORTE DSC vs ZANAFLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorzoxazone acts on the central nervous system (CNS) at the spinal cord level, possibly by depressing polysynaptic reflexes, producing skeletal muscle relaxation without affecting neuromuscular transmission.
Alpha-2 adrenergic receptor agonist; reduces sympathetic outflow from CNS, leading to decreased muscle tone and spasticity.
Adults: 4 g (500 mg x 8 tablets) orally every 6-8 hours as needed; maximum 8 g (16 tablets) per 24 hours.
Initial: 2 mg orally every 6-8 hours as needed, up to 3 times daily. Maximum: 36 mg per day.
None Documented
None Documented
1-3 hours (terminal); clinically relevant for dosing intervals of 4-6 hours.
Terminal elimination half-life is approximately 2.5 hours in healthy adults; clinically, this short half-life necessitates multiple daily dosing for sustained effect and contributes to its use as needed for spasticity.
Primarily renal (85-95% as glucuronide conjugates and unchanged drug; <5% fecal).
Approximately 95% of a dose is eliminated via hepatic metabolism; renal excretion accounts for about 20% as unchanged drug and metabolites, with about 20% eliminated in feces.
Category C
Category C
Muscle Relaxant/Analgesic Combination
Muscle Relaxant